Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.54 |
| ▸ | MGAM | O43451 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | SI | P14410 | 5/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 5/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27155060 | 0.84 | ALDH1A1 (0.54) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL3370820 | 0.84 | MEN1 (0.59) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL7047429 | 0.84 | MEN1 (0.59) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL1893849 | 0.84 | MEN1 (0.59) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL6283244 | 0.82 | GPR84 (0.59) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL4170824 | 0.81 | MAPT (0.54) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL4184199 | 0.81 | MAPT (0.54) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL1349263 | 0.81 | MEN1 (0.56) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL30518932 | 0.81 | MEN1 (0.56) | MAPTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL9250842 | 0.81 | KMT2A (0.56) | MAPTMEN1KMT2APKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1915991-B | Synthesis of indole thiazole compounds as ligands for the ah receptor | WISCONSIN ALUMNI RES FOUND | 2010-05-26 | — | — | CN | claimed |
| CN-1915991-A | Synthesis of indole thiazole compounds as ligands for the ah receptor | WISCONSIN ALUMNI RES FOUND (US) | 2007-02-21 | — | — | CN | claimed |
| CN-1642910-A | Synthesis of indole thiazole compounds as ligands for the AH receptor | WISCONSIN ALUMNI RES FOUND (US) | 2005-07-20 | — | — | CN | claimed |
| US-6046138-A | Indole derivatives and rooting inducers comprising the same as the active ingredient | SHISEIDO COMPANY, LTD. (JP) | 2000-04-04 | — | — | US | claimed |
| CN-119265092-A | Production and secretion of indole-3-acetic acid (IAA) in bacteria | 斯尼普生物群系有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-115175575-A | Engineered bacterial compositions and uses thereof | 赛里斯治疗公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
| EP-3852790-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113164571-A | Inhibition of ubiquitin-specific peptidase 9X | 福马治疗股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112512342-A | Engineered bacterial compositions and uses thereof | 赛里斯治疗公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| CN-1420880-A | Substd. N-Benzyl-indol-3-yl glyoxylic acid derivs. having anti-tumoral effect | ZENTARIS AG (DE) | 2003-05-28 | — | — | CN | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-1089744-B1 | NEUROPROTECTIVE COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF NERVOUS AND BEHAVIOURAL ALTERATIONS DUE TO ANXIETY STATES OR DEPRESSION, COMPRISING ACETYL-L-CARNITINE AND HYPERICIN | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2002-11-27 | — | — | EP | disclosed |
| US-6346282-B1 | SYNERGISTIC COMPOSITIONS FOR TREATING NERVOUS SYSTEM DISORDERS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-02-12 | — | — | US | disclosed |
| CN-1307479-A | Neuroprotective composition for preventing and/or treating nervous and behavioral disorders due to anxiety states or depression | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2001-08-08 | — | — | CN | disclosed |
| EP-1089744-A2 | NEUROPROTECTIVE COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF NERVOUS AND BEHAVIOURAL ALTERATIONS DUE TO ANXIETY STATES OR DEPRESSION, COMPRISING ACETYL-L-CARNITINE AND HYPERICIN | Sigma-Tau Healthscience S.p.A. (IT) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999066914-A2 | NEUROPROTECTIVE COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF NERVOUS AND BEHAVIOURAL ALTERATIONS DUE TO ANXIETY STATES OR DEPRESSION, COMPRISING ACETYL-L-CARNITINE AND HYPERICIN | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | MAPT 4800/4885MEN1 2361/4885KMT2A 629/4885 |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | MAPT 2208/4885MEN1 3166/4885KMT2A 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.